Rate My Professor Damian Purcell

Purcell's research focuses on molecular virology, particularly RNA-mediated regulation of HIV-1 and HTLV-1 replication and gene expression during productive and latent infection. His laboratory examines viral mRNA processing—including splicing, polyadenylation, nuclear export, translation, and degradation—as targets for novel antiviral drugs, vaccines, and therapies. Key areas include ribosome shunting mechanisms in HIV-1 env mRNAs, viral silencing in astrocytes, RNA interference as an innate antiviral defense, and development of HIV vaccines using modified HIV-1 and SIV gene expression. He leads projects on passive antibody microbicides, chronic immune activation in treated HIV disease, and RNA control of HIV-1 gene expression. Purcell has extended his expertise to SARS-CoV-2, contributing to diagnostics, genomics, vaccine assessment, and isolation of mutant strains. He holds leadership positions including Past President of the Australasian Virology Society, Chair of the Virology Division of the Australian Society for Microbiology, Co-Director of the Australian Global Virus Network Center, Chair of the ASHM HTLV-1 Working Group, and Steering Committee member of the Federal Ministerial Taskforce on HTLV. Representative publications include 'Alternative splicing of human immunodeficiency virus type 1 mRNA modulates viral protein expression, replication, and infectivity' (1996) and 'Preclinical development of a cross-protective β-SARS-CoV-2 virus-like particle vaccine adjuvanted with MF59' (2026). He has secured multimillion-dollar grants, such as $4.3 million from the Australia-Japan Research Co-operative Program for HTLV-1 treatments and Medical Research Future Fund support for mRNA vaccine manufacturing.